Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention is relevant to proteins and novel methods of protein evolution. The present invention further relates to methods of identifying and mapping mutant polypeptides formed from, or based upon, a template polypeptide.
Core Innovation
The invention provides comprehensive methods of evolving a polypeptide from a functional protein by generating sets of mutant polynucleotides and producing corresponding mutant polypeptides for assaying. In one approach, N,N,N are incorporated at every codon position in a polynucleotide encoding the functional protein to generate predetermined mutant polynucleotides containing every possible codon sequence, which are cloned and then confirmed. Mutant polypeptides are produced from the confirmed mutant polynucleotides and assayed for at least one predetermined property, characteristic or activity compared to the functional protein.
The invention also provides positional and insertion/deletion evolution approaches to generate mutant polypeptides and distinguish effects of mutations. Positional evolution categories identify sites as fully mutable, partially mutable, non-mutable, and up-mutants, and distinguish effects on function, expression, and cloning as described in the EvoMap™ functional positional map. Comprehensive Positional Evolution (CPE™) generates single-position amino-acid variant libraries, Comprehensive Positional Insertion Evolution (CPI™) inserts residues after each position, and Comprehensive Positional Deletion Evolution (CPD™) generates single-position deletions.
Combinatorial Protein Synthesis (CPS™) combines up-mutant and neutral hit information to evolve polypeptides, including Synergy Evolution and Flex Evolution embodiments. Synergy Evolution combines selected point mutations at multiple sites without structural input, while Flex Evolution enables targeted modifications at fully mutable sites, including glycosylation/conjugation and silent-codon optimization, and deimmunization-related changes. The antibody embodiments include applying these approaches to antibodies and to complementarity determining regions (CDRs) with sequencing confirmation, expression screening, and functional assays such as ELISA, as well as binding affinity evaluation.
Claims Coverage
The provided material includes two independent claims (clm-00001 and clm-00005). Each claim covers a method for evolving a polypeptide from a functional protein with defined mutant generation, confirmation, mutant production, and assaying of predetermined properties/characteristics/activities, with claim 1 requiring codon-position coverage across every codon position and claim 5 requiring N,N,N at a codon position in a template polynucleotide followed by cloning, expression, and assaying.
N,N,N incorporation at every codon position with cloning and sequencing confirmation
Incorporating N,N,N at every codon position in a polynucleotide encoding the functional protein to generate a set of predetermined mutant polynucleotides containing every possible codon sequence and cloning each predetermined mutant polynucleotide, and confirming by sequencing, or some other method, that greater than 75% of the predetermined mutant polynucleotides in the set were generated and cloned.
Producing mutant polypeptides and assaying predetermined properties compared to the functional protein
Producing a set of mutant polypeptides from the set of predetermined polynucleotides and assaying each mutant polypeptide for at least one predetermined property, characteristic or activity compared to the functional protein.
N,N,N incorporation at a codon position in a template polynucleotide with cloning and expression confirmation
Incorporating N,N,N at a codon position in a template polynucleotide encoding the functional protein to generate one or more predetermined codons within the set of mutant polynucleotides and cloning and expressing each mutant polynucleotides to produce a set of mutant polypeptides.
Sequencing or other confirmation of mutant polypeptides and assaying predetermined properties compared to the functional protein
Confirming by sequencing or some other method that greater than 75% of the mutant polypeptides in the set were generated, cloned and expressed, and assaying each mutant polypeptide for at least one predetermined property, characteristic or activity compared to the functional protein.
Across the independent claims, the inventive coverage is the generation of predetermined mutant polynucleotides by incorporating N,N,N (every codon position or at a codon position), cloning (and in claim 5 expressing) mutant polynucleotides to obtain mutant polypeptides, confirming that greater than 75% are generated (and cloned/expressed as required), and assaying each mutant polypeptide for predetermined properties/characteristics/activities relative to the functional protein.
Stated Advantages
Produces mutant polypeptides that are assayed for predetermined properties, characteristics or activities compared to the functional protein.
Confirms by sequencing, or some other method, that greater than 75% of predetermined mutant polynucleotides (or mutant polypeptides) were generated and cloned (and expressed, where required).
Documented Applications
Evolving antibodies, including antibodies in which complementarity determining regions (CDRs) are targeted, with sequencing confirmation, expression screening, and functional assays such as ELISA to evaluate changes in binding affinity.
Synergy Evolution combining selected point mutations at multiple sites without structural input for evolving polypeptides.
Flex Evolution enabling targeted modifications at fully mutable sites, including glycosylation/conjugation, silent-codon optimization, and deimmunization.
Interested in licensing this patent?